Daily Bulletin

Men's Weekly

.

CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cision

HONG KONG, July 13, 2021 /PRNewswire/ -- Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia. AK117 resulted in no dose-limiting toxicity (DLT) and no anemia of clinical...

Read more: CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to...

Business News

Car Rental as a Practical and Flexible Solution for Travel or Work

The contemporary, hectic way of life is one of ease and adaptability while commuting and working. Regardless of whether one moves around by road, commuting between towns for conferences, or taking a f...

Daily Bulletin - avatar Daily Bulletin

Car Park Markings Melbourne: How Quality Line Marking Shapes Safer Spaces

In modern busy urbanized societies, structured parking areas are necessary in terms of both security and convenience. At a shopping center, business establishment, or a publicly-accessible facility, t...

Daily Bulletin - avatar Daily Bulletin

Cleaning Australia: The Rise of Professional Cleaning Services

The cleaning industry in Australia is booming as more people are opting for professional cleaning services to keep their homes, offices, and businesses spotless. With the increasing demand for cleanli...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business